NCT03425461View on ClinicalTrials.gov

Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV Melanoma

PHASE1TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

June 14, 2018

Primary Completion Date

March 4, 2021

Study Completion Date

March 4, 2021

Conditions
Metastatic MelanomaStage III Cutaneous Melanoma AJCC v7Stage IIIA Cutaneous Melanoma AJCC v7Stage IIIB Cutaneous Melanoma AJCC v7Stage IIIC Cutaneous Melanoma AJCC v7Stage IV Cutaneous Melanoma AJCC v6 and v7
Interventions
BIOLOGICAL

Anti-SEMA4D Monoclonal Antibody VX15/2503

Given IV

BIOLOGICAL

Ipilimumab

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Nivolumab

Given IV

OTHER

Pharmacological Study

Correlative studies

Trial Locations (2)

84112

University of Utah Huntsman Cancer Institute, Salt Lake City

90095

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

Vaccinex Inc.

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

lead

Jonsson Comprehensive Cancer Center

OTHER

NCT03425461 - Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV Melanoma | Biotech Hunter | Biotech Hunter